225 related articles for article (PubMed ID: 32118712)
1. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis.
Shin S; Lee SH; Lee M; Kim JH; Lee W; Lee HW; Park MS; Park S; Kim TS; Choi DH
Medicine (Baltimore); 2020 Feb; 99(9):e19008. PubMed ID: 32118712
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.
Lee M; Chung GE; Lee JH; Oh S; Nam JY; Chang Y; Cho H; Ahn H; Cho YY; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Yoon JH
Hepatology; 2017 Nov; 66(5):1556-1569. PubMed ID: 28617992
[TBL] [Abstract][Full Text] [Related]
3. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
4. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
5. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study.
Liao YH; Hsu RJ; Wang TH; Wu CT; Huang SY; Hsu CY; Su YC; Hsu WL; Liu DW
BMC Gastroenterol; 2020 Jan; 20(1):6. PubMed ID: 31918672
[TBL] [Abstract][Full Text] [Related]
6. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
Hung TH; Liang CM; Hsu CN; Tai WC; Tsai KL; Ku MK; Wang JW; Tseng KL; Yuan LT; Nguang SH; Yang SC; Wu CK; Hsu PI; Wu DC; Chuah SK
PLoS One; 2017; 12(7):e0181858. PubMed ID: 28742130
[TBL] [Abstract][Full Text] [Related]
7. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Lee TY; Hsu YC; Tseng HC; Yu SH; Lin JT; Wu MS; Wu CY
JAMA Intern Med; 2019 May; 179(5):633-640. PubMed ID: 30882847
[TBL] [Abstract][Full Text] [Related]
8. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups.
Mancebo A; González-Diéguez ML; Cadahía V; Varela M; Pérez R; Navascués CA; Sotorríos NG; Martínez M; Rodrigo L; Rodríguez M
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):95-101. PubMed ID: 22982095
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study.
Du ZQ; Zhao JZ; Dong J; Bi JB; Ren YF; Zhang J; Khalid B; Wu Z; Lv Y; Zhang XF; Wu RQ
World J Gastroenterol; 2019 Jul; 25(28):3798-3807. PubMed ID: 31391774
[TBL] [Abstract][Full Text] [Related]
11. Relative risk of hepatocellular carcinoma in HBsAg positive vs alcoholic cirrhosis. A cross-sectional study.
Hadengue A; N'Dri N; Benhamou JP
Liver; 1990 Jun; 10(3):147-51. PubMed ID: 2166890
[TBL] [Abstract][Full Text] [Related]
12. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study.
Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
Scand J Gastroenterol; 2019 Aug; 54(8):1027-1032. PubMed ID: 31389730
[No Abstract] [Full Text] [Related]
13. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B.
Lee CH; Lee YB; Moon H; Chung JW; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
Aliment Pharmacol Ther; 2023 Oct; 58(7):704-714. PubMed ID: 37461332
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.
Yamauchi M; Nakahara M; Maezawa Y; Satoh S; Nishikawa F; Ohata M; Mizuhara Y; Hirakawa J; Nakajima H; Fujisawa K
Am J Gastroenterol; 1993 Jan; 88(1):39-43. PubMed ID: 7678368
[TBL] [Abstract][Full Text] [Related]
15. Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis.
Tan JL; Sidhu-Brar S; Woodman R; Chinnaratha MA
J Gastrointest Cancer; 2023 Jun; 54(2):325-331. PubMed ID: 35717551
[TBL] [Abstract][Full Text] [Related]
16. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
[TBL] [Abstract][Full Text] [Related]
17. Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
Yun B; Ahn SH; Yoon JH; Kim BK
Am J Gastroenterol; 2022 May; 117(5):758-768. PubMed ID: 35294425
[TBL] [Abstract][Full Text] [Related]
18. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
Jang H; Lee YB; Moon H; Chung JW; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
Hepatology; 2022 Aug; 76(2):492-501. PubMed ID: 35100447
[TBL] [Abstract][Full Text] [Related]
19. A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis.
Lee K; Choi GH; Jang ES; Jeong SH; Kim JW
Sci Rep; 2022 Feb; 12(1):1717. PubMed ID: 35110551
[TBL] [Abstract][Full Text] [Related]
20. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.
Wijarnpreecha K; Li F; Xiang Y; Xu X; Zhu C; Maroufy V; Wang Q; Tao W; Dang Y; Pham HA; Zhou Y; Li J; Zhang X; Xu H; Taner CB; Yang L; Tao C
Aliment Pharmacol Ther; 2021 Aug; 54(4):481-492. PubMed ID: 34224163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
